| 1 |
Qin T, Gu XQ, Jeong SS, et al. Impact of EBV infection and immune function assay for lymphoproliferative disorder in pediatric patients after liver transplantation: a single-center experience[J]. Hepatobiliary Pancreat Dis Int, 2020，19(1)：3-11.
|
| 2 |
Wang T, Feng M, Luo C, et al. Successful treatment of pediatric refractory Burkitt lymphoma PTLD after liver transplantation using anti-CD19 chimeric antigen receptor T-cell therapy[J]. Cell Transplant, 2021，30：963689721996649.
|
| 3 |
陈奥，练巧燕，张建恒，等. 移植后淋巴增殖性疾病研究进展[J/CD]. 中华移植杂志：电子版，2021，15(5): 307-312.
|
| 4 |
Caillard S, Porcher R, Provot F, et al. Post-transplantation lymphoproliferative disorder after kidney transplantation: report of a nationwide French registry and the development of a new prognostic score[J]. J Clin Oncol, 2013，31(10)：1302-1309.
|
| 5 |
Tajima T, Hata K, Haga H, et al. Post-transplant lymphoproliferative disorders after liver transplantation: a retrospective cohort study including 1954 transplants[J]. Liver Transpl, 2021，27(8)：1165-1180.
|
| 6 |
Wasuwanich P, Batsis I, Thawillarp S, et al. Post-transplant eosinophilic gastrointestinal disorders and lymphoproliferative disorder in pediatric liver transplant recipients on tacrolimus[J]. Transpl Immunol, 2021，68：101438.
|
| 7 |
Baker A, Frauca Remacha E, Torres Canizales J, et al. Current practices on diagnosis, prevention and treatment of post-transplant lymphoproliferative disorder in pediatric patients after solid organ transplantation: results of ERN Transplant Child Healthcare Working Group Survey[J]. Children (Basel), 2021，8(8)：661.
|
| 8 |
Éboli LPCB, Tannuri ACA, Tannuri U. Seropositivity for cytomegalovirus and PCR-EBV monitoring: protective factors for posttransplant lymphoproliferative disorder in pediatric liver transplant[J]. Pediatr Transplant, 2022，26(4)：e14226.
|
| 9 |
Akbas A, Tiede C, Lemound J, et al. Post-transplant lymphoproliferative disorders with naso- and oropharyngeal manifestation[J]. Transpl Int, 2015，28(11)：1299-1307.
|
| 10 |
Walti LN, Mugglin C, Sidler D, et al. Association of antiviral prophylaxis and rituximab use with posttransplant lymphoproliferative disorders (PTLDs): a nationwide cohort study[J]. Am J Transplant, 2021，21(7)：2532-2542.
|
| 11 |
Kampers J, Orjuela-Grimm M, Schober T, et al. Classical Hodgkin lymphoma-type PTLD after solid organ transplantation in children: a report on 17 patients treated according to subsequent GPOH-HD treatment schedules [J]. Leuk Lymphoma, 2017，58(3)：633-638.
|
| 12 |
刘静怡，孙丽莹，朱志军，等. 儿童肝移植后淋巴组织增生性疾病诊疗分析[J/CD]. 实用器官移植电子杂志，2021，9(3): 183-189.
|
| 13 |
Tsao L, Hsi ED. The clinicopathologic spectrum of posttransplantation lymphoproliferative disorders[J]. Arch Pathol Lab Med, 2007, 131(8)：1209-1218.
|
| 14 |
Ghigna MR, Reineke T, Rincé P, et al. Epstein-Barr virus infection and altered control of apoptotic pathways in posttransplant lymphoproliferative disorders[J]. Pathobiology, 2013，80(2)：53-59.
|
| 15 |
Opelz G, Daniel V, Naujokat C, et al. Epidemiology of pretransplant EBV and CMV serostatus in relation to posttransplant non-Hodgkin lymphoma[J]. Transplantation, 2009，88(8)：962-967.
|
| 16 |
Dharnidharka VR, Lamb KE, Gregg JA, et al. Associations between EBV serostatus and organ transplant type in PTLD risk: an analysis of the SRTR National Registry Data in the United States[J]. Am J Transplant, 2012，12(4)：976-983.
|
| 17 |
Dierickx D, Habermann TM. Post-transplantation lymphoproliferative disorders in adults[J]. N Engl J Med, 2018，378(6)：549-562.
|
| 18 |
Younes BS, McDiarmid SV, Martin MG, et al. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients[J]. Transplantation, 2000，70(1)：94-99.
|
| 19 |
Chardot C, Nicoluzzi JE, Janssen M, et al. Use of mycophenolate mofetil as rescue therapy after pediatric liver transplantation[J]. Transplantation, 2001，71(2)：224-229.
|
| 20 |
Sindhi R, Webber S, Venkataramanan R, et al. Sirolimus for rescue and primary immunosuppression in transplanted children receiving tacrolimus[J]. Transplantation, 2001，72(5)：851-855.
|
| 21 |
Kwong AJ, Fix OK. Update on the management of the liver transplant patient[J]. Curr Opin Gastroenterol, 2015，31(3)：224-232.
|
| 22 |
Kremers WK, Devarbhavi HC, Wiesner RH, et al. Post-transplant lymphoproliferative disorders following liver transplantation: incidence, risk factors and survival[J]. Am J Transplant, 2006，6(5 Pt 1)：1017-1024.
|
| 23 |
Zimmermann T, Hoppe-Lotichius M, Tripkovic V, et al. Liver transplanted patients with preoperative autoimmune hepatitis and immunological disorders are at increased risk for post-transplant lymphoproliferative disease (PTLD) [J]. Eur J Intern Med, 2010，21(3)：208-215.
|
| 24 |
Hézode C, Duvoux C, Germanidis G, et al. Role of hepatitis C virus in lymphoproliferative disorders after liver transplantation[J]. Hepatology, 1999，30(3)：775-778.
|
| 25 |
Kinch A, Baecklund E, Backlin C, et al. A population-based study of 135 lymphomas after solid organ transplantation: the role of Epstein-Barr virus, hepatitis C and diffuse large B-cell lymphoma subtype in clinical presentation and survival[J]. Acta Oncol, 2014，53(5)：669-679.
|
| 26 |
Zhang A, Zhang M, Shen Y, et al. Hepatitis B virus reactivation is a risk factor for development of post-transplant lymphoproliferative disease after liver transplantation[J]. Clin Transplant, 2009，23(5)：756-760.
|
| 27 |
Panagiotidis E, Quigley AM, Pencharz D, et al. (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in diagnosis of post-transplant lymphoproliferative disorder[J]. Leuk Lymphoma, 2014，55(3)：515-519.
|
| 28 |
Aguilera N, Gru AA. Reexamining post-transplant lymphoproliferative disorders: newly recognized and enigmatic types[J]. Semin Diagn Pathol, 2018，35(4)：236-246.
|
| 29 |
Hanto DW, Frizzera G, Gajl-Peczalska KJ, et al. Epstein-Barr virus-induced B-cell lymphoma after renal transplantation: acyclovir therapy and transition from polyclonal to monoclonal B-cell proliferation[J]. N Engl J Med, 1982，306(15)：913-918.
|
| 30 |
Green M, Kaufmann M, Wilson J, et al. Comparison of intravenous ganciclovir followed by oral acyclovir with intravenous ganciclovir alone for prevention of cytomegalovirus and Epstein-Barr virus disease after liver transplantation in children[J]. Clin Infect Dis, 1997，25(6)：1344-1349.
|
| 31 |
Jarasvaraparn C, Choudhury S, Rusch C, et al. Characteristics, risk factors, and outcomes of neutropenia after liver or kidney transplantation in children[J]. Pediatr Transplant, 2022，26(1)：e14131.
|
| 32 |
Trappe R, Riess H, Anagnostopoulos I, et al. Efficiency of antiviral therapy plus IVIG in a case of primary EBV infection associated PTLD refractory to rituximab, chemotherapy, and antiviral therapy alone[J]. Ann Hematol, 2009，88(2)：167-172.
|
| 33 |
Lindsay J, Othman J, Heldman MR, et al. Epstein-Barr virus posttransplant lymphoproliferative disorder: update on management and outcomes[J]. Curr Opin Infect Dis, 2021，34(6)：635-645.
|
| 34 |
Chen HS, Ho MC, Hu RH, et al. Roles of Epstein-Barr virus viral load monitoring in the prediction of posttransplant lymphoproliferative disorder in pediatric liver transplantation[J]. J Formos Med Assoc, 2019，118(9)：1362-1368.
|
| 35 |
McDiarmid SV, Jordan S, Kim GS, et al. Prevention and preemptive therapy of posttransplant lymphoproliferative disease in pediatric liver recipients[J]. Transplantation, 1998，66(12)：1604-1611.
|
| 36 |
Lee TC, Savoldo B, Rooney CM, et al. Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients[J]. Am J Transplant, 2005，5(9)：2222-2228.
|
| 37 |
Swinnen LJ, LeBlanc M, Grogan TM, et al. Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder[J]. Transplantation, 2008，86(2)：215-222.
|
| 38 |
Parker A, Bowles K, Bradley JA, et al. Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients-BCSH and BTS Guidelines[J]. Br J Haematol, 2010，149(5)：693-705.
|
| 39 |
Tsai DE, Hardy CL, Tomaszewski JE, et al. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients[J]. Transplantation, 2001，71(8)：1076-1088.
|
| 40 |
Reshef R, Vardhanabhuti S, Luskin MR, et al. Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder[J]. Am J Transplant, 2011，11(2)：336-347.
|
| 41 |
Trappe RU, Dierickx D, Zimmermann H, et al. Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful stratification into rituximab or R-CHOP consolidation in an international, prospective, multicenter phase Ⅱ trial [J]. J Clin Oncol, 2017，35(5)：536-543.
|
| 42 |
Trappe R, Oertel S, Leblond V, et al. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial[J]. Lancet Oncol, 2012，13(2)：196-206.
|
| 43 |
Dang BN, Ch′ng J, Russell M, et al. Treatment of post-transplant lymphoproliferative disorder (PTLD) in a heart transplant recipient with chimeric antigen receptor T-cell therapy[J]. Pediatr Transplant, 2021，25(5)：e13861.
|
| 44 |
Perica K, Varela JC, Oelke M, et al. Adoptive T cell immunotherapy for cancer[J]. Rambam Maimonides Med J, 2015，6(1)：e0004.
|
| 45 |
Papadopoulos EB, Ladanyi M, Emanuel D, et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation[J]. N Engl J Med, 1994，330(17)：1185-1191.
|
| 46 |
Dharnidharka VR, Mohanakumar T. New approaches to treating B-cell cancers induced by Epstein-Barr virus[J]. N Engl J Med, 2015，372(6)：569-571.
|
| 47 |
陶媛，汝昆. 移植后淋巴组织增殖性疾病的诊疗特点及进展[J/CD]. 实用器官移植电子杂志，2019, 7(5): 401-405.
|
| 48 |
Mumtaz K, Faisal N, Marquez M, et al. Post-transplant lymphoproliferative disorder in liver recipients: characteristics, management, and outcome from a single-centre experience with >1000 liver transplantations[J]. Can J Gastroenterol Hepatol, 2015，29(8)：417-422.
|